. 2013 Jul 2;13(5):353–364. doi: 10.1007/s40256-013-0035-2

Table 2.

Improvement rate after the final dose

Treatment group	Improved	Not improved	Improvement rate [% (95 % CI)]	Superiority relative to the PP group^a	Dose-dependency between LM and MH groups^b
PP group (N = 48)	0	48	0.0 (0.0–0.0)
LM group (N = 48)	29	19	60.4 (46.6–74.3)	PP vs. LM p = 0.0001
MH group (N = 50)	21	29	42.0 (28.3–55.7)	PP vs. MH p = 0.0001	LM vs. MH p = 0.1050

Treatment group

Improved

Not improved

Improvement rate [% (95 % CI)]

Superiority relative to the PP group^a

Dose-dependency between LM and MH groups^b

PP group (N = 48)

0.0 (0.0–0.0)

LM group (N = 48)

60.4 (46.6–74.3)

PP vs. LM

p = 0.0001

MH group (N = 50)

42.0 (28.3–55.7)

PP vs. MH

p = 0.0001

LM vs. MH

p = 0.1050

Refer to Table 1 for treatment group definitions

CI confidence interval

^aChi-square test; significance was defined as p < 0.025 (two-tailed) based on Bonferroni correction

^bChi-square test; significance was defined as p < 0.05 (two-tailed)